



## Commercial/Healthcare Exchange PA Criteria

*Effective: January 1, 2020*

**Prior Authorization:** Oseni (alogliptin benzoate/pioglitazone hydrochloride) oral tablets

**Products Affected:** Oseni tablets, alogliptin/pioglitazone tablets

**Medication Description:** Oseni is a fixed-dose combination product of alogliptin benzoate and pioglitazone hydrochloride combines 2 antihyperglycemic agents which act differently to achieve glycemic control in patients with type 2 diabetes. Alogliptin benzoate is a dipeptidyl peptidase-4 (DPP-4) inhibitor that reduces fasting and postprandial glucose concentrations in a glucose-dependent manner by slowing the inactivation of incretin hormones (eg, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by binding to and inhibiting the DPP-4 enzyme. Pioglitazone hydrochloride, a member of the thiazolidinedione class, works as an insulin-sensitizing agent to improve peripheral glucose utilization.

**Covered Uses:** Is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and pioglitazone is appropriate.

**Exclusion Criteria:**

1. Hypersensitivity to alogliptin, pioglitazone, or to any component of the product
2. NYHA Class III or IV heart failure

**Required Medical Information:**

1. Diagnosis
2. Chart Notes

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:** Approve if the following criteria is met:

1. Patient has the diagnosis of type 2 diabetes mellitus; AND
2. Patient has experienced an inadequate treatment response, intolerance, or contraindication to Januvia AND Tradjenta.

**References:**

Product Information: OSENI oral tablets, alogliptin pioglitazone oral tablets. Takeda Pharmaceuticals America, Inc. (per manufacturer), Deerfield, IL, 2013.

Last Reviewed October 21, 2019



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/21/2019